1361030-62-7

Basic information

• Product Name: N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-4-(2-(dimethylamino)ethyl)-1-(4-fluorophenyl)-1H-pyrazole-3-carboxamide
• Synonyms: N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-4-(2-(dimethylamino)ethyl)-1-(4-fluorophenyl)-1H-pyrazole-3-carboxamide
• CAS NO: 1361030-62-7
• Molecular Weight: 573.599
• Mol File: 1361030-62-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-4-(2-(dimethylamino)ethyl)-1-(4-fluorophenyl)-1H-pyrazole-3-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-4-(2-(dimethylamino)ethyl)-1-(4-fluorophenyl)-1H-pyrazole-3-carboxamide(1361030-62-7)
• EPA Substance Registry System: N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-4-(2-(dimethylamino)ethyl)-1-(4-fluorophenyl)-1H-pyrazole-3-carboxamide(1361030-62-7)

Safety Data

• Hazardous Substances Data: 1361030-62-7(Hazardous Substances Data)

Upstream product

• 636568-08-6 ethyl 1-(4-fluorophenyl)-4-hydroxy-1H-pyrazole-3-carboxylate 
• 1361031-17-5 ethyl 4-chloro-2-(4-fluorophenyl)azo-3-oxo-butanoate 
• 371-40-4 4-fluoroaniline 
• 1361031-37-9 4-(2-dimethylaminoethyl)-1-(4-fluorophenyl)pyrazole-3-carboxylic acid 
• 347161-74-4 4-[(6,7-dimethoxyquinolin-4-yl)oxy]-3-fluoroaniline 
• 1361031-38-0 ethyl 4-(2-(dimethylamino)ethyl)-1-(4-fluorophenyl)-1H-pyrazole-3-carboxylate 
• 369-34-6 3,4-difluoronitrobenzene 
• 13425-93-9 6,7-dimethoxyquinoline-4-ol 
• 516526-44-6 4-(2-fluoro-4-nitro-phenoxy)-6,7-dimethoxy-quinoline 

Relevant articles and documents

Pharmaceutically active compounds as Axl inhibitors

The present invention relates to 1-nitrogen-heterocyclic-2-carboxamides of general formula (I): and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the treatment and/or prevention of Axl receptor tyrosine kinase subfamily induced disorders, including cancer and primary tumor metastases, and pharmaceutical compositions containing at least one of said 1-nitrogen-heterocyclic-2-carboxamide derivatives and/or pharmaceutically acceptable salts thereof.